Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
Patrick L. Fitzgibbons,David L. Page,Donald L. Weaver,Ann D. Thor,Allred Dc,Gary M. Clark,Stephen G. Ruby,O'Malley F,Simpson Jf,James L. Connolly,Daniel F. Hayes,Stephen B. Edge,Lichter A,Stuart J. Schnitt +13 more
TLDR
This report constitutes a detailed outline of the findings and recommendations of the consensus conference group, organized according to structural guidelines as defined.Abstract:
BACKGROUND Under the auspices of the College of American Pathologists, a multidisciplinary group of clinicians, pathologists, and statisticians considered prognostic and predictive factors in breast cancer and stratified them into categories reflecting the strength of published evidence. MATERIALS AND METHODS Factors were ranked according to previously established College of American Pathologists categorical rankings: category I, factors proven to be of prognostic import and useful in clinical patient management; category II, factors that had been extensively studied biologically and clinically, but whose import remains to be validated in statistically robust studies; and category III, all other factors not sufficiently studied to demonstrate their prognostic value. Factors in categories I and II were considered with respect to variations in methods of analysis, interpretation of findings, reporting of data, and statistical evaluation. For each factor, detailed recommendations for improvement were made. Recommendations were based on the following aims: (1) increasing uniformity and completeness of pathologic evaluation of tumor specimens, (2) enhancing the quality of data collected about existing prognostic factors, and (3) improving patient care. RESULTS AND CONCLUSIONS Factors ranked in category I included TNM staging information, histologic grade, histologic type, mitotic figure counts, and hormone receptor status. Category II factors included c-erbB-2 (Her2-neu), proliferation markers, lymphatic and vascular channel invasion, and p53. Factors in category III included DNA ploidy analysis, microvessel density, epidermal growth factor receptor, transforming growth factor-alpha, bcl-2, pS2, and cathepsin D. This report constitutes a detailed outline of the findings and recommendations of the consensus conference group, organized according to structural guidelines as defined.read more
Citations
More filters
Journal ArticleDOI
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik,Steven Shak,Gong Tang,Chungyeul Kim,Joffre B. Baker,Maureen T. Cronin,Frederick L. Baehner,Michael G. Walker,Drew Watson,Taesung Park,William Hiller,Edwin R. Fisher,D. Lawrence Wickerham,John Bryant,Norman Wolmark +14 more
TL;DR: The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.
Journal ArticleDOI
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond,Daniel F. Hayes,Mitch Dowsett,D. Craig Allred,Karen L. Hagerty,Sunil V. Badve,Patrick L. Fitzgibbons,Glenn Francis,Neil S. Goldstein,Malcolm Hayes,David G. Hicks,Susan C. Lester,Richard Love,Pamela B. Mangu,Lisa M. McShane,Keith Miller,C. Kent Osborne,Soonmyung Paik,Jane Perlmutter,Anthony Rhodes,Hironobu Sasano,Jared N. Schwartz,Fred C.G.J. Sweep,Sheila E. Taube,Emina Torlakovic,Paul N. Valenstein,Giuseppe Viale,Daniel W. Visscher,Thomas M. Wheeler,R. Bruce Williams,James L. Wittliff,Antonio C. Wolff +31 more
TL;DR: An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Alfred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.
Journal ArticleDOI
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
Christos Sotiriou,Pratyaksha Wirapati,Sherene Loi,Adrian L. Harris,Steve Fox,Johanna Smeds,Hans Nordgren,Pierre Farmer,Viviane Praz,Benjamin Haibe-Kains,Christine Desmedt,Denis Larsimont,Fatima Cardoso,Hans Peterse,Dimitry S.A. Nuyten,Marc Buyse,Marc J. van de Vijver,Jonas Bergh,Martine Piccart,Mauro Delorenzi +19 more
TL;DR: Gene expression grade index appeared to reclassify patients with histologic grade 2 tumors into two groups with high versus low risks of recurrence, which may improve the accuracy of tumor grading and thus its prognostic value.
References
More filters
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
p53, the Cellular Gatekeeper for Growth and Division
TL;DR: The author regrets the lack of citations for many important observations mentioned in the text, but their omission is made necessary by restrictions in the preparation of review manuscripts.
Journal ArticleDOI
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Dennis J. Slamon,William Godolphin,Lovell A. Jones,John A. Holt,Steven G. Wong,Duane E. Keith,Wendy J. Levin,Susan G. Stuart,Judy Udove,Axel Ullrich,Michael F. Press +10 more
TL;DR: The concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers, including breast and ovarian cancer, is supported.
Journal ArticleDOI
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
TL;DR: The number of microvessels per 200x field in the areas of most intensive neovascularization in an invasive breast carcinoma may be an independent predictor of metastatic disease either in axillary lymph nodes or at distant sites (or both).
Journal ArticleDOI
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C. W. Elston,Ian O. Ellis +1 more
TL;DR: The results demonstrate that this method for histological grading provides important prognostic information and, if the grading protocol is followed consistently, reproducible results can be obtained.
Related Papers (5)
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C. W. Elston,Ian O. Ellis +1 more
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more